 Amanda Winters
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 18 | 2024 | 630 | 3.320 |
Why?
| | Azacitidine | 10 | 2024 | 140 | 2.150 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 14 | 2025 | 227 | 2.090 |
Why?
| | Neoplasm, Residual | 5 | 2024 | 133 | 2.020 |
Why?
| | Sulfonamides | 13 | 2025 | 513 | 1.690 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2025 | 1692 | 1.540 |
Why?
| | Myelodysplastic Syndromes | 4 | 2020 | 135 | 1.000 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 289 | 0.810 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 123 | 0.660 |
Why?
| | Graft vs Host Disease | 1 | 2022 | 252 | 0.660 |
Why?
| | Neoplastic Stem Cells | 6 | 2025 | 399 | 0.650 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2022 | 622 | 0.650 |
Why?
| | Peripheral Nervous System Neoplasms | 1 | 2017 | 18 | 0.540 |
Why?
| | Neurilemmoma | 1 | 2017 | 24 | 0.540 |
Why?
| | Hemangiosarcoma | 1 | 2017 | 21 | 0.540 |
Why?
| | Neurofibromatosis 1 | 1 | 2017 | 52 | 0.520 |
Why?
| | Immunotherapy | 1 | 2019 | 641 | 0.460 |
Why?
| | Mutation | 1 | 2024 | 3958 | 0.400 |
Why?
| | Polymerase Chain Reaction | 2 | 2024 | 1062 | 0.330 |
Why?
| | Prognosis | 4 | 2024 | 4030 | 0.330 |
Why?
| | Estrogen Receptor alpha | 1 | 2010 | 145 | 0.310 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2025 | 801 | 0.300 |
Why?
| | Glycoproteins | 1 | 2010 | 342 | 0.300 |
Why?
| | Receptors, Estrogen | 1 | 2010 | 436 | 0.280 |
Why?
| | Humans | 32 | 2025 | 137585 | 0.270 |
Why?
| | Carrier Proteins | 1 | 2010 | 771 | 0.250 |
Why?
| | Leukemia | 3 | 2018 | 240 | 0.250 |
Why?
| | Retrospective Studies | 8 | 2024 | 15657 | 0.230 |
Why?
| | Iron Overload | 1 | 2024 | 17 | 0.220 |
Why?
| | Follow-Up Studies | 4 | 2024 | 5131 | 0.220 |
Why?
| | Aged, 80 and over | 5 | 2024 | 7635 | 0.210 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2025 | 122 | 0.210 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 2 | 2019 | 17 | 0.190 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.190 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 48 | 0.180 |
Why?
| | DNA Copy Number Variations | 1 | 2022 | 182 | 0.180 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2022 | 346 | 0.180 |
Why?
| | Burkitt Lymphoma | 1 | 2022 | 60 | 0.180 |
Why?
| | Child | 7 | 2024 | 21935 | 0.180 |
Why?
| | Central Nervous System Neoplasms | 1 | 2023 | 156 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2022 | 139 | 0.170 |
Why?
| | Disease-Free Survival | 1 | 2022 | 686 | 0.170 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 206 | 0.160 |
Why?
| | Oxidative Phosphorylation | 4 | 2024 | 193 | 0.160 |
Why?
| | Anemia, Sickle Cell | 1 | 2023 | 270 | 0.150 |
Why?
| | Recurrence | 1 | 2022 | 1060 | 0.150 |
Why?
| | Antigens, CD19 | 1 | 2019 | 123 | 0.150 |
Why?
| | Antibodies, Bispecific | 1 | 2019 | 55 | 0.150 |
Why?
| | Remission Induction | 1 | 2019 | 288 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 916 | 0.150 |
Why?
| | Female | 10 | 2024 | 73304 | 0.150 |
Why?
| | Calcium | 1 | 2024 | 1199 | 0.150 |
Why?
| | Salvage Therapy | 1 | 2019 | 142 | 0.140 |
Why?
| | Mitochondria | 1 | 2024 | 948 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 383 | 0.140 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 2 | 2009 | 70 | 0.140 |
Why?
| | Male | 9 | 2024 | 67762 | 0.140 |
Why?
| | Aged | 6 | 2024 | 23961 | 0.140 |
Why?
| | Young Adult | 5 | 2022 | 13209 | 0.140 |
Why?
| | Treatment Outcome | 2 | 2024 | 10811 | 0.140 |
Why?
| | Adult | 5 | 2024 | 37929 | 0.130 |
Why?
| | Hematopoietic Stem Cells | 2 | 2018 | 406 | 0.130 |
Why?
| | Genetic Testing | 1 | 2019 | 460 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 327 | 0.130 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 327 | 0.120 |
Why?
| | Homeostasis | 1 | 2018 | 621 | 0.110 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 658 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3284 | 0.110 |
Why?
| | Computational Biology | 1 | 2019 | 644 | 0.110 |
Why?
| | Stroke | 1 | 2023 | 1120 | 0.110 |
Why?
| | Peptide Fragments | 2 | 2009 | 706 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1996 | 0.110 |
Why?
| | Nuclear Proteins | 2 | 2009 | 712 | 0.100 |
Why?
| | Glucose | 1 | 2018 | 1020 | 0.100 |
Why?
| | Middle Aged | 4 | 2024 | 33479 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1079 | 0.100 |
Why?
| | Apoptosis | 3 | 2018 | 2553 | 0.100 |
Why?
| | Adenocarcinoma, Papillary | 1 | 2010 | 12 | 0.090 |
Why?
| | Infant | 2 | 2024 | 9465 | 0.080 |
Why?
| | Thyroidectomy | 1 | 2010 | 106 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2018 | 1208 | 0.080 |
Why?
| | Adolescent | 4 | 2024 | 21513 | 0.080 |
Why?
| | Child, Preschool | 2 | 2024 | 11074 | 0.080 |
Why?
| | Membrane Transport Proteins | 1 | 2010 | 162 | 0.080 |
Why?
| | Neoplasms | 1 | 2024 | 2671 | 0.080 |
Why?
| | Tumor Cells, Cultured | 3 | 2022 | 955 | 0.070 |
Why?
| | Signal Transduction | 1 | 2022 | 5079 | 0.070 |
Why?
| | Gene Rearrangement | 1 | 2009 | 150 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3412 | 0.070 |
Why?
| | Thyroid Neoplasms | 1 | 2010 | 343 | 0.060 |
Why?
| | Stem Cells | 2 | 2020 | 594 | 0.060 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2007 | 215 | 0.060 |
Why?
| | Blast Crisis | 1 | 2025 | 33 | 0.060 |
Why?
| | Mice | 4 | 2025 | 17787 | 0.060 |
Why?
| | Transfusion Reaction | 1 | 2024 | 45 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 88 | 0.050 |
Why?
| | Gene Fusion | 1 | 2022 | 27 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 76 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2009 | 1502 | 0.040 |
Why?
| | Allografts | 1 | 2021 | 146 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2022 | 318 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2018 | 1178 | 0.040 |
Why?
| | Niacinamide | 1 | 2020 | 82 | 0.040 |
Why?
| | Animals | 4 | 2025 | 36940 | 0.040 |
Why?
| | Cancer Survivors | 1 | 2024 | 285 | 0.040 |
Why?
| | Lentivirus | 1 | 2019 | 56 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 10 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 16 | 0.040 |
Why?
| | Electron Transport Complex II | 1 | 2018 | 26 | 0.040 |
Why?
| | Succinate Dehydrogenase | 1 | 2018 | 50 | 0.040 |
Why?
| | Cell Survival | 1 | 2022 | 1120 | 0.040 |
Why?
| | Colony-Forming Units Assay | 2 | 2009 | 91 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 367 | 0.040 |
Why?
| | Translocation, Genetic | 2 | 2009 | 105 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2022 | 1738 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 233 | 0.030 |
Why?
| | Fatty Acids | 1 | 2020 | 443 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 601 | 0.030 |
Why?
| | Necrosis | 2 | 2009 | 246 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 247 | 0.030 |
Why?
| | Amino Acids | 1 | 2020 | 497 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2018 | 4193 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2757 | 0.030 |
Why?
| | Blotting, Western | 2 | 2009 | 1226 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1972 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2031 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2129 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2018 | 922 | 0.020 |
Why?
| | Risk Factors | 1 | 2024 | 10388 | 0.020 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2009 | 30 | 0.020 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2009 | 41 | 0.020 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2009 | 59 | 0.020 |
Why?
| | Cytarabine | 1 | 2009 | 61 | 0.020 |
Why?
| | Transcriptional Elongation Factors | 1 | 2009 | 40 | 0.020 |
Why?
| | Etoposide | 1 | 2009 | 158 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2009 | 94 | 0.020 |
Why?
| | Drug Synergism | 1 | 2009 | 382 | 0.020 |
Why?
| | Comet Assay | 1 | 2007 | 16 | 0.020 |
Why?
| | Insulin | 1 | 2018 | 2409 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2009 | 191 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2007 | 124 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2007 | 72 | 0.020 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2009 | 136 | 0.020 |
Why?
| | Cell Cycle | 1 | 2009 | 601 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2007 | 620 | 0.010 |
Why?
| | Cell Membrane | 1 | 2007 | 738 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 2475 | 0.010 |
Why?
|
|
Winters's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|